The last patient has now completed the full treatment period in IRLAB’s Phase IIb study with pirepemat

Gothenburg, Sweden, January 14, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces that all patients enrolled in the Phase IIb study with the drug candidate pirepemat (REACT-PD) have completed their final follow-up visit. Topline data from the study are expected in the first quarter of 2025.

IRLAB to present at ABGSC Investor Days on December 4, 2024

IRLAB to present at Redeye Technology & Life Science Day on December 3, 2024